|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics. CA Cancer J Clin. 62:10–29. 2012.
|
|
2
|
Yang GF, Li XM and Xie D: Overexpression
of clusterin in ovarian cancer is correlated with impaired
survival. Int J Gynecol Cancer. 19:1342–1346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Trougakos IP and Gonos ES:
Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem
Cell Biol. 34:1430–1448. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rizzi F and Bettuzzi S: Clusterin (CLU)
and prostate cancer. Adv Cancer Res. 105:1–19. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Albert JM, Gonzalez A, Massion PP, Chen H,
Olson SJ, Shyr Y, Diaz R, Lambright ES, Sandler A, Carbone DP,
Putnam JJ, Johnson DH and Lu B: Cytoplasmic clusterin expression is
associated with longer survival in patients with resected non small
cell lung cancer. Cancer Epidemiol Biomarkers Prev. 16:1845–1851.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pucci S, Bonanno E, Pichiorri F, Angeloni
C and Spagnoli LG: Modulation of different clusterin isoforms in
human colon tumorigenesis. Oncogene. 23:2298–2304. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Redondo M, Villar E, Torres-Munoz J,
Tellez T, Morell M and Petito CK: Overexpression of clusterin in
human breast carcinoma. Am J Pathol. 157:393–399. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miyake H, Gleave M, Kamidono S and Hara I:
Overexpression of clusterin in transitional cell carcinoma of the
bladder is related to disease progression and recurrence. Urology.
59:150–154. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lau SH, Sham JS, Xie D, Tzang CH, Tang D,
Ma N, Hu L, Wang Y, Wen JM, Xiao G, Zhang WM, Lau GK, Yang M and
Guan XY: Clusterin plays an important role in hepatocellular
carcinoma metastasis. Oncogene. 25:1242–1250. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Senger DR, Galli SJ, Dvorak AM, Perruzzi
CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular
permeability factor that promotes accumulation of ascites fluid.
Science. 219:983–985. 1983. View Article : Google Scholar
|
|
11
|
Connolly DT, Olander JV, Heuvelman D,
Nelson R, Monsell R, Siegel N, Haymore BL, Leimgruber R and Feder
J: Human vascular permeability factor. Isolation from U937 cells. J
Biol Chem. 264:20017–20024. 1989.PubMed/NCBI
|
|
12
|
Geva E and Jaffe RB: Role of vascular
endothelial growth factor in ovarian physiology and pathology.
Fertil Steril. 74:429–438. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ramakrishnan S, Subramanian IV, Yokoyama Y
and Geller M: Angiogenesis in normal and neoplastic ovaries.
Angiogenesis. 8:169–182. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Belotti D, Paganoni P, Manenti L, Garofalo
A, Marchini S, Taraboletti G and Giavazzi R: Matrix
metalloproteinases (MMP9 and MMP2) induce the release of vascular
endothelial growth factor (VEGF) by ovarian carcinoma cells:
implications for ascites formation. Cancer Res. 63:5224–5229.
2003.
|
|
15
|
Matei D, Kelich S, Cao L, Menning N,
Emerson RE, Rao J, Jeng MH and Sledge GW: PDGF BB induces VEGF
secretion in ovarian cancer. Cancer Biol Ther. 6:1951–1959. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liao S, Liu J, Lin P, Shi T, Jain RK and
Xu L: TGF-beta blockade controls ascites by preventing
abnormalization of lymphatic vessels in orthotopic human ovarian
carcinoma models. Clin Cancer Res. 17:1415–1424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cao Z, Fang J, Xia C, Shi X and Jiang BH:
*************trans-3,4,5′-Trihydroxystibene inhibits
hypoxia-inducible factor 1α and vascular endothelial growth factor
expression in human ovarian cancer cells. Clin Cancer Res.
10:5253–5263. 2004.
|
|
18
|
Masoumi MS, Amini A, Morris DL and
Pourgholami MH: Significance of vascular endothelial growth factor
in growth and peritoneal dissemination of ovarian cancer. Cancer
Metastasis Rev. 31:143–162. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu LZ, Hu XW, Xia C, He J, Zhou Q, Shi X,
Fang J and Jiang BH: Reactive oxygen species regulate epidermal
growth factor-induced vascular endothelial growth factor and
hypoxia-inducible factor-1alpha expression through activation of
AKT and P70S6K1 in human ovarian cancer cells. Free Radic Biol Med.
41:1521–1533. 2006. View Article : Google Scholar
|
|
20
|
Jones PA and Baylin SB: The fundamental
role of epigenetic events in cancer. Nat Rev Genet. 3:415–428.
2002.PubMed/NCBI
|
|
21
|
Hassan MK, Watari H, Han Y, Mitamura T,
Hosaka M, Wang L, Tanaka S and Sakuragi N: Clusterin is a potential
molecular predictor for ovarian cancer patient’s survival:
targeting clusterin improves response to paclitaxel. J Exp Clin
Cancer Res. 30:1132011.PubMed/NCBI
|
|
22
|
Ferrara N, Hillan KJ and Novotny W:
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody
for cancer therapy. Biochem Biophys Res Commun. 333:328–335. 2005.
View Article : Google Scholar : PubMed/NCBI
|
